Apatinib, also known as rivoceranib, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2...
8 KB (798 words) - 20:06, 30 November 2023
and talazoparib) PI3K inhibitors (e.g. perifosine in a phase III trial) Apatinib is a selective VEGF Receptor 2 inhibitor which has shown encouraging anti-tumor...
20 KB (2,234 words) - 01:21, 22 July 2024
objective response rate with median progression free survival of 6.1 months Apatinib: 3% objective response rate with median progression free survival of 18...
21 KB (2,187 words) - 14:39, 28 May 2024
fluzoparib for solid cancers, especially prostate cancer; A VEGFR2 inhibitor apatinib as a combination therapy. Trials were also performed in the fields of metabolic...
6 KB (475 words) - 00:10, 22 April 2024
function have to be made to modify doses before the therapy can start. Apatinib is used for the treatment of advanced gastric cancer. It is often diagnosed...
51 KB (4,735 words) - 08:15, 2 January 2024
system, etc., and is well known for its innovative anti-cancer drugs. Apatinib, e.g., which was approved by China FDA (CFDA) in December 2014, has been...
90 KB (12,115 words) - 03:24, 15 July 2024